PSKY — Paramount Skydance Corporation Class B Common Stock

Sentiment is polarized rather than directional. The Street shows 8 Buy / 10 Hold / 11 Sell (consensus rating 'Sell'), institutional 13Fs show funds trimming or pausing adds, and prediction markets price roughly a 25% chance the WBD deal fails — all of which keeps the stock pinned near $10.40-10.60 even after Q2 2026 beat consensus and management raised FY2026 adjusted EBITDA guidance to $3.8-3.9B. The lone $18 price target comes from a single analyst after the Skydance merger reset coverage, so the headline upside is low-confidence. As of 2026-09-13 the tape reads neutral: RSI 56.4, above the 20-day (+0.07%) and 50-day (+10.25%) but still 2.8% below the 200-day, with a +11.6% 1-month return following a -2.4% week.

The top line is structurally flat, not growing: quarterly revenue has sat in a $6.7-8.5B band for three years, and Q2 2026's $6.91B was only ~1% above Q2 2025's $6.85B. Reported earnings are extremely noisy because of non-cash impairments tied to the Skydance combination -- Q2 2024 posted -$8.12 diluted EPS (a ~$5.4B net loss) and Q4 2025 posted -$6.93B of operating income -- which is an accounting event, not cash leaving the business (stockholders' equity fell from $16.7B in Q2 2025 to ~$11.8B by Q2 2026 for the same reason). Strip that out and the underlying trend is a genuine, recent inflection: Q2 2026 operating income was +$475M, adjusted EBITDA rose 27% YoY to $1.10B, Paramount+ reached 81.6M subscribers, and Q2 2026 operating cash flow was $319M vs. $159M a year earlier. Net read: flat revenue, volatile GAAP earnings, improving cash generation and EBITDA -- a mid-turnaround, not a structural collapse, though the 14-week/transition periods in the data mean some sequential comparisons are apples-to-oranges.

Split signals. On trailing GAAP it looks broken: TTM P/E -18.9 and EPS -$0.556, because impairments and interest swamp reported profit. On asset and cash-flow measures it looks cheap-ish: P/B 1.006 (equity $11.77B is ~$10.82/share), P/S 0.392 (vs. a 3-year average of ~0.36), and EV of ~$24.4B against ~$3.85B of guided FY2026 adjusted EBITDA is ~6.3x EV/EBITDA. On forward earnings it looks expensive: 21.1x the $0.502 next-FY consensus EPS, and TTM free cash flow of ~$404M is a thin 3.5% FCF yield versus $11.5B of market cap (~60x FCF on an EV basis). My read is 'fair-to-slightly-cheap on assets/EBITDA, rich on earnings/FCF' -- the market is capitalizing the EBITDA recovery, not today's GAAP profits. That roughly matches the deterministic score's 'Neutral vs. its own history' label, though P/S slightly above its own 3-year average argues marginally rich on sales.

The gap between adjusted EBITDA ($3.8-3.9B guided) and GAAP EPS ($0.50 forward) is the entire story: heavy interest expense on ~$14.5B of debt plus large content/D&A amortization consume most of the EBITDA before it reaches equity holders. At $10.60 the stock pays ~21x forward EPS, which already discounts an earnings recovery that has not shown up in GAAP numbers yet -- so a buyer here is underwriting the EBITDA-to-EPS conversion, not buying cheap current earnings. If management hits its raised EBITDA guide and EPS inflects toward $1.00+, the effective multiple compresses to 11-13x and the stock can re-rate; if interest and content costs keep eating the EBITDA, EPS stays stuck near $0.50 and the optical P/E stays rich. Watch the adjusted-EBITDA-to-GAAP-EPS bridge every quarter -- that, not revenue, is the swing variable.

As of 2026-09-13: RSI(14) 56.4 -- neutral, no overbought/oversold edge. Price is barely above the 20-day SMA (+0.07%) and comfortably above the 50-day (+10.25%), but still 2.8% below the 200-day -- a recovering downtrend that has not yet confirmed. Returns: -2.4% 1-week, +11.6% 1-month, +1.2% 3-month, +9.1% 6-month -- choppy, range-bound to up, not a clean trend. Entry implication: no urgency here; the informative setups are either a decisive reclaim of the 200-day (~$10.90-11.00) on volume for momentum buyers, or accumulation nearer $9.50-10.00 support for value buyers. Sitting right at the 200-day is the least informative spot on the chart.

• Interest-rate/debt-refinancing environment: with ~$14.5B of long-term debt and 1.29x debt-to-equity, every basis point matters; elevated rates raise the cost of the $110B WBD acquisition and constrain deleveraging.
• Antitrust/regulatory: the DOJ cleared the WBD deal in June 2026 but 12 state AGs plus the WGA are litigating, with a trial set for March 2027 -- an unusually state-driven regulatory risk for a media combination.
• Secular linear-TV decline and the streaming transition: cord-cutting keeps pressuring affiliate fees and advertising at CBS/MTV/Nickelodeon while streaming still requires heavy content spend.
• Advertising cyclicality: ad revenue across CBS and Pluto TV is tied to the broader ad market, layering macro sensitivity on top of structural change.
• Media-sector M&A and rotation sentiment: the market is pricing a consolidation wave, so peer deal news and political/regulatory appetite move PSKY by association.

• Late-October 2026 court-mandated settlement talks with the state AGs over WBD merger remedies (divestitures, behavioral conditions, bond postings).
• Q3 2026 earnings in early November 2026 -- the first test of whether subscriber growth can offset the guided sequential profit dip.
• March 2, 2027 trial date on the state antitrust suit seeking to permanently block the WBD combination.
• Delivery on FY2026 adjusted EBITDA guidance of $3.8-3.9B plus further Paramount+ subscriber growth beyond 81.6M.
• Improving free cash flow funding potential asset sales, buybacks, or balance-sheet repair.

• Balance sheet: ~$14.5B long-term debt, 1.29x debt-to-equity, a current ratio of just 1.04, and $1.63B of cash leave a thin cushion against content-funding needs.
• WBD merger execution and legal risk: ~25% market-implied failure probability, plus 'ticking fees' and delay costs; if it closes, leverage balloons further.
• Structural linear-TV erosion outpacing streaming profitability, keeping revenue flat and margins thin.
• Earnings-quality/impairment risk: several of the last ten quarters carried large write-downs, and equity has fallen ~$5B since mid-2025, so book value is not a hard floor.
• Thin post-merger analyst coverage (a single $18 price target) makes the stock more volatile on estimate revisions and harder to underwrite on consensus.

Not an attractive risk/reward at $10.60 right now. The operational story is genuinely improving -- adjusted EBITDA +27% YoY, guidance raised, 81.6M streaming subs, positive and growing operating cash flow -- but the equity sits behind ~$14.5B of debt, GAAP earnings are thin and noisy, the forward P/E (~21x) already prices a recovery that has not shown up, and the single biggest swing factor (the $110B WBD bid) is a binary, litigated event with a March 2027 trial. With a base-case fair value near $12.50, the upside is roughly 18% against a fat left tail -- accelerating cord-cutting or a deal collapse could send the stock back toward its $7.62 low. The asymmetry is unfavorable until either the 200-day is reclaimed on volume or merger clarity arrives.

I applied a 6.75x EV/EBITDA multiple -- a modest premium to the ~6.3x the market currently pays, justified by the raised FY2026 adjusted EBITDA guide of $3.8-3.9B and the streaming inflection, but below the 8-9x less-levered media peers command -- to forward EBITDA of ~$4.0B, giving ~$27.0B of enterprise value; subtracting ~$12.9B of net debt and dividing by ~1.088B shares yields ~$13.00, which I haircut to $12.50 for deal-failure/breakup and ticking-fee risk. Cross-checks: ~1.0x book is $10.82/share, and ~$1B of run-rate free cash flow at a 12x multiple is ~$11.00, bracketing the estimate.